Cue Biopharma, Inc. Proceeds from Debt, Net of Issuance Costs
Cue Biopharma, Inc. (CUE) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-03-16
- Cue Biopharma, Inc. proceeds from debt, net of issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Cue Biopharma, Inc. proceeds from debt, net of issuance costs for fiscal 2024 was $18.00K.
- Cue Biopharma, Inc. proceeds from debt, net of issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Cue Biopharma, Inc. proceeds from debt, net of issuance costs for fiscal 2022 was $4.70M.
| Period end | Proceeds from Debt, Net of Issuance Costs 12 month | Proceeds from Debt, Net of Issuance Costs 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-16 | |
| 2024-12-31 | $18.00K 10-K · filed 2026-03-16 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |
| 2022-12-31 | $4.70M 10-K · filed 2024-03-28 | $4.70M 10-K · filed 2023-03-21 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |